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Background Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients
with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One
of the adverse effects of RAAS blockade is the development of hyperkalaemia, which often limits the optimization
of recommended, Class I treatments. In this context, potassium binders patiromer or sodium zirconium cyclosili-
cate (ZS-9) provide an opportunity to optimize the pharmacological management of these patients.
...................................................................................................................................................................................................
Case summary We present a case report illustrating our real-life experience using the potassium-binder patiromer in a patient
with HFrEF, in whom recurrent hyperkalaemia (up to 6.3 mmol/L with low doses of enalapril) was preventing titra-
tion of RAAS inhibition therapies. Use of patiromer allowed re-introducing ramipril (subsequently switched to
sacubitril/valsartan) and eplerenone. Serum potassium levels remained normal with patiromer 16.8 g/24 h, and the
patient’s tolerance to patiromer was excellent.
...................................................................................................................................................................................................
Discussion In patients with HFrEF and recurrent hyperkalaemia, optimal RAAS inhibition is often discontinued. In this context,
novel potassium binders such as patiromer or ZS-9 have been shown to be effective in lowering potassium and
maintaining normokalaemia, with a good safety profile and patient tolerance, all of which make them promising al-
ternative options. Our preliminary experience suggests that patiromer may be a helpful and well-tolerated treat-
ment option, which may aid in achieving optimal RAAS inhibition in HFrEF patients with recurrent hyperkalaemia.
Registries of HFrEF patients will help better understand whether therapies such as patiromer have prognostic ben-
efits through facilitating optimal RAAS blockade.
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Introduction
Chronic heart failure (CHF) is a growing public health problem.1
Around half of the patients with CHF have a left ventricular ejection
fraction (LVEF) below 40%—so-called ‘heart failure with reduced
ejection fraction’ (HFrEF).2,3 A major cornerstone of medical therapy
in these patients is the inhibition of the renin–angiotensin–aldoster-
one system (RAAS).2,3 An undesirable effects of RAAS blockade is
the development of hyperkalaemia (defined as serum potassium lev-
els > 5.0 mmol/L),4 a condition which often prevents optimizing Class
I pharmacotherapies such as angiotensin-converting enzyme inhibi-
tors (ACEIs)5 or mineralocorticoid receptor antagonists (MRAs),6 a
failure which is likely to have prognostic implications.4
In this context, novel treatments for hyperkalaemia such as
patiromer or sodium zirconium cyclosilicate (ZS-9) provide an op-
portunity to ameliorate this issue.4,7,8 These potassium binders have
been recently approved by the Food and Drug Administration (FDA)
and European Medicines Agency (EMA) (FDA approval in 2015 and
EMA approval in 2017 for patiromer use, and both FDA and EMA
approvals for ZS-9 use in 2018).9 Nevertheless, the real-world ex-
perience with these therapies is currently limited.
Timeline
Case presentation
We present a 74-year-old Caucasian male with a history of Type 2
diabetes mellitus, hypertension, hypercholesterolaemia, former to-
bacco use, chronic pulmonary obstructive disease, and chronic kid-
ney disease (CKD) Stage 3 [baseline estimated glomerular filtration
rate (eGFR) ranging 40–50 mL/min]. Relevant cardiac history
included atrial fibrillation and ischaemic heart disease with an acute
myocardial infarction (AMI) in 2009; the angiography showed coron-
ary disease: chronic total occlusion of the right coronary artery and
severe stenosis of the proximal left anterior descending artery,
treated percutaneously with a drug-eluting stent.
After the AMI, the patient’s LVEF was <40%, and he developed
HFrEF. He presented several acute decompensations requiring hos-
pital admissions between 2011 and July 2017. In the latter admission,
echocardiography showed a dilated left ventricle (end-diastolic vol-
ume: 67 mL/m2), LVEF 34%, moderate functional mitral regurgitation,
normal right ventricle without pulmonary hypertension. A stress
echocardiography was performed, showing no ischaemia and no sig-
nificant worsening of mitral regurgitation. The patient was discharged
in a New York Heart Association (NYHA) functional Class IIb, with
suboptimal medical therapy.
It was then when the patient began follow-up in the multidisciplin-
ary CHF management programme, which included intensive health
education, and careful pharmacological titration. During follow-up,
low doses of an ACEI (enalapril), a beta-blocker (nebivolol), and
June 2017 Discharge after acute heart failure hospitalization. Follow-up in multidisciplinary chronic care management programme
July 2017 Enalapril 10 mg þ eplerenone 25 mg
August 2017 Enalapril þ eplerenone discontinuation [Potassium (Kþ) 6.3 mmol/L]
September 2017 Ramipril 1.25 mg
October 2017 Ramipril discontinuation (Kþ 6.1 mmol/L)
November–December 2017 Hospital admission due to acute heart failure
December 2017 Discharge after acute heart failure hospitalization. Ramipril 2.5 mg þ patiromer 8.4 g
January 2018 Ramipril 2.5 mg þ patiromer 16.8g (Kþ 5.4 mmol/L)
February 2018 Ramipril 5 mg þ patiromer 16.8 g
March 2018 Ramipril 5 mg þ eplerenone 12.5 mg þ patiromer 16.8 g
April 2018 Ramipril 5 mg þ eplerenone 25 mg þ patiromer 16.8 g
May 2018 Ramipril discontinuation
Sacubitril/valsartan 24/26 mg þ eplerenone 25 mg þ patiromer 16.8 g
Learning points
• Hyperkalaemia may prevent the optimization of therapy in patients with chronic heart failure (CHF) impacting prognosis.
• Calcium/sodium polystyrene sulphonates, a common treatment to avoid recurrent hyperkalaemia in clinical practice in Europe, has a
lack of evidence in its efficacy and is associated with side effects.
• New potassium binders such as patiromer or zirconium cyclosilicate can be an important treatment option to avoid hyperkalaemia in
patients with chronic conditions as CHF and chronic kidney disease.












































































MRA (eplerenone) were initiated sequentially, as per current clinical
practice guidelines.
Up-titration of beta-blockers up to 10 mg/day was successfully
achieved after 2 months. The same did not occur with enalapril and
eplerenone: both had to be discontinued 2 weeks after initiating
eplerenone due to deterioration of renal function and hyperkalaemia
(eGFR 30 mL/min, Kþ 6.3 mmol/L). There were no clinical manifes-
tations, no significant arrhythmias and both T wave and the QRS
complex remained unaltered in the electrocardiogram. Blood tests
showed a recovery of renal function and potassium levels 1 week
after (eGFR 39 mL/min, Kþ 4.9 mmol/L). A few weeks later, in a se-
cond attempt to use ACEIs, low doses of ramipril (1.25 mg/24 h)
were initiated. Despite the very low dose, Kþ levels raised again up
to 6.1 mmol/L (eGFR unchanged). Ramipril was discontinued, and the
patient was once again questioned about dietary habits, with no evi-
dence of intake of potassium-rich foods, supplements, or other pre-
ventable causes of hyperkalaemia.
To facilitate further attempts to optimally inhibit the RAAS, cal-
cium polystyrene sulphonate was introduced. Nevertheless, the pa-
tient spontaneously abandoned treatment due to self-reported
gastric intolerance. During this period, the patient suffered a new
acute decompensation of CHF in the context of a respiratory infec-
tion, leading to acute pulmonary oedema.
Certain that was unable to achieve optimal RAAS inhibition due to
recurrent hyperkalaemia, we requested special permission to use
patiromer, a potassium binder which had not been commercialized in
Europe by then. After discharge (eGFR 50 mL/min, Kþ 4.6 mmol/L)
patiromer 8.4 g/24 h and ramipril 2.5 mg/24 h were initiated simultan-
eously. The laboratory tests 3 days later showed serum potassium
levels of 5.4 mmol/L, eGFR 53 mL/min. Ramipril was maintained, and
the dose of patiromer was doubled (16.8 g/24 h); subsequent blood
test showed serum potassium levels back to normal (4.9 mmol/L).
Ramipril was then up-titrated to 5 mg/24 h, without evidence of
hyperkalaemia in the subsequent controls. MRAs were then reintro-
duced. First, 12.5 mg/24 h of eplerenone, potassium levels being per-
sistently <5 mmol/L, followed by up-titration to 25 mg/24 h. The
patient’s subjective tolerance was excellent, and blood tests consist-
ently showed stable eGFRs and potassium levels.
Given the persistent NYHA Class IIb, during follow-up, ramipril was
replaced by an angiotensin receptor blocker neprilysin inhibitor (sacu-
bitril/valsartan 24/26 mg), with no recurrence of significant hyperkalae-
mia. There were no substantial differences in renal function or
electrolytes before and after patiromer initiation, except potassium
levels. Creatinine and eGFR levels ranged 130–150mmol/L and 40–
50 mL/min, respectively, and phosphate levels ranged 1.1–1.2 mmol/L.
Magnessemia ranged 0.6–0.7 mmol/L, i.e. compatible with mild hypo-
magnesemia, which was present before patiromer initiation and was
not worsened by therapy. It has not been possible to further up-titrate
RAAS inhibitors due to arterial hypotension (persistent asymptomatic
systolic blood pressure below 90 mmHg). The patient is now in
NYHA Class IIa and has had no recent decompensations.
After 3 months under optimal medical therapy, follow-up echocar-
diography has recently been performed, showing no significant
changes: the left ventricle remained dilated, with an LVEF of 35%. The
patient will soon receive an implantable cardioverter-defibrillator.
Discussion
We present a case report illustrating the real-life use of potassium-
binder patiromer in a patient with HFrEF and recurrent hyperkalae-
mia, which precluded optimal RAAS inhibition. In these patients, clin-
ical practice guidelines recommend looking for reversible causes
(diet, supplements, drugs) and correcting them.2–4 Lowering or dis-
continuation of RAAS inhibitors is recommended when potassium
levels are >5.5 mmol/L.2–4
Although clinical experience with potassium binders in patients
with CHF and CKD is accumulated for calcium/sodium polystyrene
sulphonate, clinical trial evidence on its efficacy is lacking and its pro-
longed use may be associated with severe side effects, such as bowel
necrosis.10,11 Also, patient tolerance is usually poor, mainly due to
gastrointestinal symptoms. In this context, novel potassium binders
such as patiromer and ZS-9, both of which have been shown to be ef-
fective in lowering potassium and maintaining normokalaemia in
patients with CHF, CKD, and hyperkalaemia, with a good safety pro-
file and patient tolerance,7,8 appear as promising alternative
options.12
Patiromer is an oral non-absorbed polymer, which exchanges cal-
cium and Kþ in the colon, resulting in increased Kþ excretion.
Drug–drug interactions are uncommon, and there are no significant
systemic side effects. The most frequent include gastrointestinal
symptoms (i.e. diarrhoea, constipation) and non-serious electrolyte
abnormalities (i.e. hypomagnesaemia). Sodium zirconium cyclosilicate
is an inorganic cation that eliminates excess potassium in the gastro-
intestinal tract. In clinical trials, the short-term safety profile of ZS-9
seems similar to placebo; studies with longer follow-up are needed.
In a recent review of potassium binders among CKD, there were
encouraging outcomes in maintaining normokalaemia and RAAS
inhibitors in patients with eGFR between 15 and 60 mL/min. There
are also some positive real-world data in patients in haemodialysis
under patiromer.11
Our preliminary experience suggests that patiromer may be a
helpful treatment to achieve optimal RAAS inhibition, preventing
hyperkalaemia and enabling up-titration of Class IA drugs in CHF
patients. Large registries of HFrEF patients will help better character-
ize the effectiveness of these novel therapies, as well as identify the
subgroups of patients most likely to benefit.
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